The core idea of this proposal is that: (a) substances released by neurons trigger the activation of glia, & (b) this glial activation, in turn, leads to the release of glial products that induce & maintain pain facilitation. It is clear from prior studies that spinal cord glia (microglia and astrocytes) become activated in response to signaling by small diameter sensory afferents. It is also clear from prior studies that blocking either glial activation or the action of glial products prevents & reverses diverse enhanced pain states. What is not understood is the signal(s) released by neurons which cause(s) such glial activation. The overall goal of this proposal is to understand this key step. We have recently discovered one putative neuron-to-glia signal so will focus on it. This signal is fractalkine, a protein tethered to the exterior surface of spinal cord neurons & sensory afferents. When neurons become strongly activated, fractalkine can break free to form a diffusible signal. We have shown in spinal cord that (a) microglia (& possibly astrocytes) express receptors for fractalkine; (b) injecting fractalkine induces thermal hyperalgesia & mechanical allodynia; & (c) early evidence suggests that fractalkine may potentially be an important signal for initiating & maintaining neuropathic pain. We propose to use a multidisciplinary approach to examine fractalkine-induced neuron-to-glia communication. First, we will define how critical fractalkine is for the induction & long-term maintenance of neuropathic pain by (a) testing the effect of a selective fractalkine receptor antagonist delivered prior to, or up to 3 months after, nerve damage & (b) testing knockouts for both fractalkine and its receptor (CX3CR1). Second, we will define the effects of fractalkine on microglia versus astrocytes using a combination of approaches: pharmacological, immunohistochemical, in vitro & adoptive transfer (intrathecal injection of in vitro stimulated microglia & astrocytes). Last, as time permits, we will examine whether fractalkine creates pain facilitation via proinflammatory cytokine release &/or """"""""priming"""""""" of gila. Together, this series of studies will provide new insights into how fractalkine in particular, & neuron-to-gila signaling in general, creates & maintains pain facilitation. Understanding this key step between neural activation & glial activation may have implications for developing new approaches for pain control.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA017670-03
Application #
7166086
Study Section
Somatosensory and Chemosensory Systems Study Section (SCS)
Program Officer
Thomas, David A
Project Start
2005-03-01
Project End
2009-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
3
Fiscal Year
2007
Total Cost
$315,710
Indirect Cost
Name
University of Colorado at Boulder
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
007431505
City
Boulder
State
CO
Country
United States
Zip Code
80309
Ellis, Amanda; Grace, Peter M; Wieseler, Julie et al. (2016) Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury. Brain Behav Immun 58:348-356
Wieseler, Julie; Sprunger, David; Ellis, Amanda et al. (2012) Indwelling supradural catheters for induction of facial allodynia: surgical procedures, application of inflammatory stimuli, and behavioral testing. Methods Mol Biol 851:99-107
Wieseler, Julie; Ellis, Amanda; Maier, Steven F et al. (2012) Unilateral T13 and L1 dorsal root avulsion: methods for a novel model of central neuropathic pain. Methods Mol Biol 851:171-83
Liu, Liang; Coller, Janet K; Watkins, Linda R et al. (2011) Naloxone-precipitated morphine withdrawal behavior and brain IL-1? expression: comparison of different mouse strains. Brain Behav Immun 25:1223-32
Lewis, S S; Hutchinson, M R; Rezvani, N et al. (2010) Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience 165:569-83
Hutchinson, Mark R; Zhang, Yingning; Shridhar, Mitesh et al. (2010) Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 24:83-95
Hutchinson, M R; Loram, L C; Zhang, Y et al. (2010) Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience 168:551-63
Loram, Lisa C; Harrison, Jacqueline A; Chao, Lindsey et al. (2010) Intrathecal injection of an alpha seven nicotinic acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine profiles in rats. Brain Behav Immun 24:959-67
Hutchinson, M R; Lewis, S S; Coats, B D et al. (2010) Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 167:880-93
Ramos, K M; Lewis, M T; Morgan, K N et al. (2010) Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. Neuroscience 169:1888-900

Showing the most recent 10 out of 26 publications